-
Mashup Score: 1Muvalaplin as an Inhibitor of Lipoprotein(a) Formation - 9 month(s) ago
This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in humans.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 9Significance of lipids, lipoproteins, and apolipoproteins during the first 14–16 months of life - 9 month(s) ago
AbstractBackground and Aims. The aims of this study were to investigate lipid parameters during the first 14–16 months of life, to identify influential factors,
Source: academic.oup.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 21Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society - 9 month(s) ago
Abstract. Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despi
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
Local GP leaders across the south of England have told practices not to follow the NHS’s advice to prescribe the cholesterol lowering drug inclisiran because of concerns over funding and long term safety monitoring. The pushback comes amid a drive by NHS England, which published funding guidance in April 2023,1 and local integrated care boards (ICBs) to make the drug available in primary care to help tackle cardiovascular disease. The National Institute for Health and Care Excellence (NICE) approved inclisiran—made by Novartis and marketed as Leqvio—in 2021,23 hailing it as “a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.” Administered by injection, inclisiran uses RNA interference to boost the liver’s ability to remove low density lipoprotein cholesterol (LDL-C) from the blood. However, the BMA, the Royal College of General Practitioners,45 and experts writing in The BMJ 6 have raised concerns about inclisiran being ini
Source: www.bmj.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
August 14, 2023 — Patients often experience functional decline after an ischemic stroke, especially due to the brain’s resistance to regenerate after damage. Yet, there is still potential for recovery as surviving neurons can activate repair mechanisms to limit and even reverse the damage caused by the stroke. How is it triggered though? In a study published recently in Neuron, researchers from Tokyo Medical and Dental University (TMDU) provided new insights regarding this question by identifying a new mechanism. They discovered that neurons surrounding the area of cell death secrete lipids that can trigger brain-autonomous neural repair after ischemic brain injury. An ischemic stroke occurs when the blood supply to the brain is blocked and results in the death of brain cells. This condition is life-threatening, and patients will likely develop functional disabilities. Although the adult brain can self-repair, the underlying mechanisms need further clarification. Inflammation of t
Source: www.dicardiology.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1‘Lipid paradox’ may obscure cardiovascular risk in patients with inflammatory disease - 10 month(s) ago
AUSTIN, Texas — Providers should carefully consider the “lipid paradox” when monitoring cardiovascular risks in patients with rheumatic inflammatory diseases, noted a presenter at the 2023 Rheumatology Nurses Society annual conference.According to Kathryn Dao, MD, FACP, FACR, of the University of Texas Southwestern Medical Center, patients with active inflammatory disease,
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 19Pitavastatin to Prevent Cardiovascular Disease in HIV Infection | NEJM - 10 month(s) ago
Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Source: www.nejm.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0USPSTF: Insufficient Evidence for Recommendation on Screening for Lipid Disorders in Asymptomatic Children - 10 month(s) ago
Reaffirming their 2016 recommendation, the USPSTF concluded current evidence was insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents in their latest recommendation statement.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Chez qui et pourquoi doser la Lp(a) ? - 10 month(s) ago
La Lp(a)Publié le 20 juin 2023- Durée : 00:06:24Dr Pierre Sabouret, Cardiologue à Paris Attention, pour des raisons réglementaires ce site est réservé aux professionnels de santé. pour voir la suite, inscrivez-vous gratuitement. Si vous êtes déjà inscrit,connectez vous : Se connecter Si vous n’êtes pas encore inscrit au site,inscrivez-vous gratuitement : Je m’inscris
Source: Cardiologie PratiqueCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Measuring Atherogenic Lipids: Does One Equation Rise Above? - 10 month(s) ago
Drs Pam Taub and Seth Martin explore the myriad of options to measure atherogenic lipids and the ongoing debate of whether an optimal assessment exists in lipid and CVD risk management.
Source: MedscapeCategories: Cardiologists, Latest HeadlinesTweet
Especially after this article https://t.co/5ePUtP4RBI #LLT #Lipids #Cardiotwitter